<DOC>
	<DOCNO>NCT01569178</DOCNO>
	<brief_summary>This multinational , multicentre , randomise open-label , control , parallel-group phase III study . Its aim demonstrate single intracoronary infusion autologous bone marrow-derived mononuclear cell safe reduces all-cause mortality patient reduce left ventricular ejection fraction ( &lt; /=45 % ) successful reperfusion acute myocardial infarction compare control group patient undergo best medical care .</brief_summary>
	<brief_title>BAMI . The Effect Intracoronary Reinfusion Bone Marrow-derived Mononuclear Cells ( BM-MNC ) All Cause Mortality Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>men woman ethnic origin aged≥18years patient acute STelevation myocardial infarction define universal definition AMI ( include new LBBB ) Patients acute STelevation myocardial infarction define universal definition AMI . Successful acute reperfusion therapy ( residual stenosis visually &lt; 50 % TIMI flow ≥2 ) within 24 hour symptom onset thrombolysis within 12 hour symptom onset follow successful percutaneous coronary intervention ( PCI ) within 24 hour thrombolysis Left ventricular ejection fraction ≤ 45 % significant regional wall motion abnormality assess quantitative echocardiography ( central , independent core lab analysis ) 2 6 day reperfusion therapy Open coronary artery suitable cell infusion supply target area abnormal wall motion Participation another clinical trial within 30 day prior randomisation Previously receive stem/progenitor cell therapy Pregnant nursing woman Mental condition render patient unable understand nature , scope possible consequence study follow protocol Necessity revascularise additional vessel , outside target coronary artery time progenitor cell infusion ( additional revascularisations , e.g . time acute PCI , permit ) allow ) , unless clinically indicate accord late guideline . This decision make time index procedure explicitly state time . Cardiogenic shock require mechanical support Platelet count &lt; 100.000/µl , hemoglobin &lt; 8.5 g/dl Impaired renal function , i.e . creatinine &gt; 2.5 mg/dl Fever diarrhea within 4 week prior screen History bleed disorder within 3 month prior screen Uncontrolled hypertension ( systolic &gt; 180 mmHg diastolic &gt; 120 mmHg ) Life expectancy less two year noncardiac cause uncontrolled neoplastic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stem cell</keyword>
	<keyword>acute myocardial infarction</keyword>
	<keyword>heart failure</keyword>
	<keyword>heart attack</keyword>
	<keyword>bone marrow</keyword>
	<keyword>intracoronary reinfusion</keyword>
	<keyword>bone marrow derive mononuclear cell</keyword>
	<keyword>Left ventricular function improvement</keyword>
	<keyword>mortality</keyword>
</DOC>